Jefferies Group LLC Rigel Pharmaceuticals Inc Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $85,905 - $133,501	-38,696 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $91,322 - $138,144	38,696 New	38,696 $45,000
Q4 2019 Feb 13, 2020	SELL	$1.6 - $2.43 $27,396 - $41,608	-17,123 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$1.63 - $2.62 $27,910 - $44,862	17,123 New	17,123 $32,000
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $96,990 - $128,511	-48,495 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $60,122 - $97,120	-28,905 Reduced 37.34%	48,495 $112,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $88,920 - $122,778	34,200 Added 79.17%	77,400 $248,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $122,256 - $177,552	43,200 New	43,200 $122,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.